Healthesystems is attending and sponsoring the Kids’ Chance National Conference, a national gathering of the Kids’ Chance community.
Healthesystems is attending the IAIABC Forum, a conference discussing policy and administrative issues in workers' comp.
Approval Date: Jan 2025
A combination NSAID and triptan drug indicated for the acute treatment of migraine with or without aura
Approval Date: Jan 2025
An NMDA receptor antagonist, this drug is now indicated for use as a monotherapy for treatment-resistant depression (TRD). Spravato originally required conjunctive use with an oral antidepressant for (TRD)
Approval Date: Jan 2025
A biosimilar to Acterma, this drug is indicated for the treatment of rheumatoid arthritis, giant cell arthritis, and COVID-19 in hospitalized patients receiving supplemental oxygen and corticosteroids
Approval Date: Jan 2025
A novel, first-in-class, non-opioid analgesic indicated for the treatment of moderate to severe acute pain. Journavx targets pain-signaling pathways involving sodium channels and has not been studied for use beyond 14 days
Approval Date: Dec 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the once-daily treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Dec 2024
A biosimilar to Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis
Approval Date: Dec 2024
An SSRI indicated for the treatment of major depressive disorder (MDD)
Approval Date: Nov 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Sep 2024
A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis
Approval Date: Aug 2024
Indicated for the treatment of opioid-induced constipation
Approval Date: Aug 2024
An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.
Approval Date: Aug 2024
Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
Approval Date: Aug 2024
Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis
Approval Date: Jul 2024
Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate
Approval Date: Jul 2024
Indicated for the treatment of mild to moderate dementia of the Alzheimer's type
